1 vegetable capsule per serving | 60 servings | Liposomal vitamin C material from a phospholipid complex 350 mg | Zinc 10 mg from zinc bisglycinate | Custom order
The word liposomal does not answer the main purchasing questions. A brand needs to know what the 350 mg line represents, how much active vitamin C it delivers, what phospholipid system is used and what evidence confirms the dry material’s structure. HEKONA confirms those points in the technical file before approving the formula and does not promise better absorption from the delivery-system name alone.
| Ingredient | Amount per serving |
| Liposomal vitamin C from phospholipid complex | 350 mg stated material amount / active basis to confirm |
| Zinc from zinc bisglycinate | 10 mg |
| Serving size | 1 vegetable capsule |
| Servings per container | 60 |
The current facts describe 350 mg of liposomal vitamin C from a phospholipid complex. That wording may refer to the complete complex or to a declared vitamin C amount, depending on the approved specification and label structure. The source document must settle the basis.
A quotation should show the raw-material input, vitamin C assay, phospholipid contribution and any carrier separately. The commercial specification and label should then use the same basis as the final Supplement Facts and batch calculation.
For a capsule, the liposomal ingredient is handled as a dry powder. Supplier documentation should explain the composition, manufacturing process, phospholipid source, assay, particle characterization and conditions under which the structure is measured.
A marketing name or raw-material description is not enough to prove superior delivery in the finished capsule. If the brand wants a comparison with ordinary ascorbic acid, the evidence must match the selected commercial material, serving and intended claim.
The formula lists 10 mg zinc from zinc bisglycinate. That amount should be presented as elemental zinc, with compound input calculated from the supplier assay. It adds a clear supporting nutrient without changing the primary liposomal vitamin C purchasing intent.
This formula differs from the zinc and copper dose design and from the conventional vitamin C, D3 and zinc capsule. Those products have separate decisions around mineral ratio or a three-nutrient format.
The 350 mg dry complex, zinc compound, carriers and excipients must fit the selected vegetable shell. Actual bulk density and flow determine the fill weight and capsule size. A pilot fill should also check capsule closure and weight variation.
The zinc amount is much smaller than the main material input. The blending sequence and any premix should support uniform distribution at commercial scale. Finished testing needs to follow the same active declaration used on the label.
Phospholipid-containing powders may require attention to oxidation, moisture and storage. The supplier handling instructions, packaging barrier, closure, seal and desiccant decision should be reviewed for the actual commercial grade.
The current record states 60 servings. Do not publish a shelf-life claim, count or storage promise until the final bottle and stability plan agree with the approved formula.
This product has no ready-stock designation. HEKONA needs the intended market and the selected liposomal material specification before confirming sample work, MOQ, production timing or pricing.
Send the supplier file if the ingredient is nominated, or state the required vitamin C declaration, phospholipid source, capsule shell, count, claim direction and forecast quantity. The response can then address formula feasibility, testing and packaging without relying on the delivery-system name alone.
The current record does not settle whether 350 mg is the active amount or total complex input. Confirm the supplier specification and final Supplement Facts.
Not from the ingredient name alone. Comparative absorption language needs evidence for the exact material, dose and intended claim.
It can be assessed as a reformulation. Source changes may affect allergen review, assay, particle evidence, stability, capsule fill and label wording.
Provide the destination market, approved ingredient specification, active vitamin C basis, phospholipid source, capsule count and expected volume. HEKONA will review the formula, testing route, packaging, MOQ and quotation.
This formula is intended for adults looking for a vitamin C supplement using a phospholipid-based delivery system with added zinc.
It may suit product lines targeting:
Final target-user wording, directions and claims should be reviewed for the intended sales market before label approval.
Whether you’re exploring new solutions, seeking technical support, or ready to start a project,our team is here to listen and collaborate.
